A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2017
At a glance
- Drugs DMI 9523 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Ampio Pharmaceuticals
- 18 Sep 2017 Planned End Date changed from 30 Nov 2017 to 11 Dec 2017.
- 18 Sep 2017 Planned primary completion date changed from 30 Nov 2017 to 11 Dec 2017.
- 18 Sep 2017 According to an Ampio Pharmaceuticals media release, enrollment and dosing of patients has been completed for this trial.